Marian Chu

1 week ago | bioworld.com | Marian Chu

Home » Remegen’s lupus drug surfaces with phase III myasthenia gravis data BioWorld briefs for April 14, 2025. BioWorld MedTech briefs for April 14, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

1 week ago | bioworld.com | Marian Chu

Kelun posts phase I/II data of China’s first TROP2 ADC for NSCLCPhase I/II trial results of sacituzumab tirumotecan (sac-TMT; Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.) published in Nature Medicine came a month after China’s National Medical Products Administration gave clearance to Kelun-Biotech’s supplemental NDA of sac-TMT to treat advanced non-small-cell lung cancer (NSCLC). BioWorld BioWorld Asia Regulatory Cancer Antibody-drug conjugate Asia-Pacific China U.S. NDA NMPA

2 weeks ago | bioworld.com | Marian Chu

AI-enhanced mammogram readings are better, but ignoredAI could significantly improve the value of patient recalls following mammography, but so far radiologists seem reluctant to rely on computer-aided readings. Radiologists tend to trust their own judgment – and that of their colleagues – in mammogram readings far more than AI-based diagnostics, even when the AI was much more accurate, a prospective trial analysis published in Radiology by Karolinska Institutet researchers found.

2 weeks ago | bioworld.com | Marian Chu

Impact of Trump tariffs on med tech proving difficult to anticipateThe Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...

2 weeks ago | bioworld.com | Marian Chu

Home » South Korea clears world’s first recombinant anthrax vaccineSouth Korea clears world’s first recombinant anthrax vaccineSouth Korea’s Ministry of Food and Drug Safety on April 8 cleared Barythrax injection (GC-1009) as the world’s first recombinant anthrax vaccine. The product was codeveloped by GC Biopharma Corp. and Korea Disease Control and Prevention Agency. BioWorld BioWorld Asia Financings Regulatory Respiratory Vaccine Series B Asia-Pacific U.S. MOHW